<h1>Introduction: Thyroid hormones (TH) are key regulators of essential cellular processes, including proliferation, differentiation, apoptosis, and metabolism. Thyroid hormones have an important role in the development of prostate cancer. So this study aims to assess thyroid function tests among prostatic cancer patients.</h1> <p><em>methods</em>: Total group study100, fifty Prostatic cancer patients as a case study and 50 healthy men as the control group, blood samples were collected for measurement for thyroid function test and Prostate Antigen by Tosoh^TM device (China) and enzyme-linked immune sorbent assay (ELISA) Fortress ^TM.            </p> <p><em>Results</em>: Statistical analysis of test results of the case study: the mean and SD±   PSA= (31.8 ± 12.5 ) , T3 = (3.3 ± 1.3) , T4 = (119.58 ± 46.21 ) and TSH =(4.6 ± 3.4) . For each P-value 0.0001 when compared to the control group, the frequency of thyroid disorders among case study participants is hyperthyroidism (33 = 66%), normal (14 = 28%), and hypothyroidism (3 = 6%).</p> <p> <em>Conclusion</em>: Hyperthyroidism is the most common thyroid disorder among patients with prostatic cancer. </p>